Expert Opinion on Pharmacotherapy最新文献_第3页

An update on the pharmacological management of acne vulgaris: the state of the art. 药物治疗寻常痤疮的最新进展：最新技术。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-20 DOI: 10.1080/14656566.2024.2418986

Isabel Cristina Valente Duarte de Sousa

{"title":"An update on the pharmacological management of acne vulgaris: the state of the art.","authors":"Isabel Cristina Valente Duarte de Sousa","doi":"10.1080/14656566.2024.2418986","DOIUrl":"10.1080/14656566.2024.2418986","url":null,"abstract":"Introduction: Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit that affects approximately 9.4% of the global population. Current treatment strategies aim to target as many pathogenic factors involved in the appearance of acne lesions and are centered on a systematic treatment escalation based on disease severity, extension, and treatment response, starting with topical treatments for mild cases and progressing over to systemic therapies in more severe cases. A literature search, which included clinical guidelines, clinical studies, and review articles on acne treatment and maintenance, was conducted to review the pharmacological approaches currently available to treat this disease.Areas covered: Topical therapies such as topical retinoids, benzoyl peroxide, azelaic acid, salicylic acid, topical antibiotics, and clascoterone, as well as systemic treatments such as oral antibiotics and isotretinoin are discussed in detail. Combined oral contraceptives and spironolactone will not be discussed in this article.Expert opinion: There is a need for a blockbuster acne drug that simultaneously targets the four main pathogenic factors involved in the appearance of acne lesions while presenting with minimal side effects. Until such a drug exists, combination therapy will remain the standard of treatment for most acne patients.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2177-2190"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging treatment modalities for fibrodysplasia ossificans progressiva. 纤维增生性骨质疏松症的现有和新兴治疗模式。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-28 DOI: 10.1080/14656566.2024.2422548

Dilan Gençel, Nejla Nur Erbil, Şeniz Demiryürek, Abdullah Tuncay Demiryürek

{"title":"Current and emerging treatment modalities for fibrodysplasia ossificans progressiva.","authors":"Dilan Gençel, Nejla Nur Erbil, Şeniz Demiryürek, Abdullah Tuncay Demiryürek","doi":"10.1080/14656566.2024.2422548","DOIUrl":"10.1080/14656566.2024.2422548","url":null,"abstract":"Introduction: Heterotopic ossification (HO), acquired or hereditary, is a diverse pathological condition defined by the production of extraskeletal bone in muscles, soft tissues, and connective tissues. Acquired HO is relatively prevalent and develops mostly in response to trauma, although its etiology is unknown. Genetic forms provide insight into the pathobiological mechanisms of this disorder. Fibrodysplasia ossificans progressiva (FOP) is a rare hereditary form of HO that can have a significant impact on affected individuals. FOP steadily weakens affected subjects and increases their risk of death.Areas covered: The U.S. Food and Drug Administration has recently approved the retinoid palovarotene as the first compound to treat heterotopic ossification in patients with FOP. This review provides a comprehensive overview of current and potential future pharmacotherapeutic options and their modes of action. The online databases PubMed, Cochrane Library, Web of Science, and ClinicalTrials.gov were searched using the terms 'heterotopic ossification' and 'fibrodysplasia ossificans progressiva' or synonyms, with a special focus over the last 5 years of publications.Expert opinion: Approval of palovarotene, as the first retinoid indicated for reduction in the volume of new HO, may revolutionize the therapeutic landscape. However, long-term safety and efficacy data for palovarotene are currently lacking.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2225-2234"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142497721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacological management of heart failure: a patient-centred approach. 心力衰竭的药物治疗：以患者为中心的方法。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-11-11 DOI: 10.1080/14656566.2024.2418414

Guglielmo Fibbi, Ryosuke Sato, Mirela Vatic, Frederik Pascal Genreith, Stephan von Haehling

{"title":"Pharmacological management of heart failure: a patient-centred approach.","authors":"Guglielmo Fibbi, Ryosuke Sato, Mirela Vatic, Frederik Pascal Genreith, Stephan von Haehling","doi":"10.1080/14656566.2024.2418414","DOIUrl":"10.1080/14656566.2024.2418414","url":null,"abstract":"Introduction: Heart failure (HF) is a global health challenge that requires a multidisciplinary approach. Despite recent advances in pharmacological and interventional therapy, morbidity and mortality in these patients remain high. For this reason, and because of its interplay with other cardiovascular and non-cardiovascular diseases, HF represents a major area of research, with new trials being published every year and international guidelines constantly updated.Areas covered: The authors review the current status and possible future developments in HF pharmacotherapy.Expert opinion: The treatment of HF has made significant advances in recent years, and the current recommendations are based on large outcome trials. This has led to significant reductions in both mortality and morbidity, but the death rate remains unacceptably high. In this context, a patient-centered approach that considers comorbidities and specific clinical scenarios when dosing HF medication is essential. Prevention of hospital admissions for cardiac decompensation is of utmost importance in patients with HF as is the enablement of activities of daily living, an endpoint which has only recently been incorporated into major HF trials.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2151-2165"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes. 糖尿病和糖尿病前期患者勃起功能障碍的药物治疗策略。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-11-05 DOI: 10.1080/14656566.2024.2422547

Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Linda Vignozzi, Alessandra Sforza, Mario Maggi

{"title":"Pharmacotherapeutic strategies for the management of erectile dysfunction in patients with diabetes and pre-diabetes.","authors":"Giovanni Corona, Giulia Rastrelli, Clotilde Sparano, Linda Vignozzi, Alessandra Sforza, Mario Maggi","doi":"10.1080/14656566.2024.2422547","DOIUrl":"10.1080/14656566.2024.2422547","url":null,"abstract":"Introduction: Erectile dysfunction (ED) is a neglected complication in patients with pre-diabetes or diabetes mellitus (DM).Areas covered: A summary and review of the role of standard ED treatment and the contribution of lifestyle modification and hypoglycemic drugs.Expert opinion: Oral phosphodiesterase type 5 inhibitors (PDE5i) represent the first-line therapy even in patients with DM. Testosterone replacement therapy (TRT) is mandatory in all hypogonadal (total testosterone < 12 nmol/l) subjects. Alprostadil and/or combined approaches can be considered when PED5i with or without TRT fail. The glycometabolic optimization through lifestyle modification and the use of hypoglycemic drugs represents a crucial step, even for ED treatment. Considering the strong association between ED and forthcoming cardiovascular diseases, the selection of glucagon-like peptide type 1 analogues or sodium glucose cotransporter-2 inhibitors seems to represent the best option due to their long-term effect on chronic complication prevention. Metformin can be considered a possible alternative in less complicated subjects. Penile prostheses (PP) can be offered when all other options are not effective, but the patients should be informed that poor glycometabolic control can increase the risk of PP infection.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2213-2223"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142582663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Investigating recent advances in pharmacotherapy for acute and chronic ocular pain post-cataract surgery. 研究白内障手术后急慢性眼痛药物疗法的最新进展。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-28 DOI: 10.1080/14656566.2024.2421323

Pragnya R Donthineni, Wade Munger, Anat Galor

引用次数: 0

Shadows and lights in sepsis immunotherapy. 败血症免疫疗法中的光与影

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-21 DOI: 10.1080/14656566.2024.2418987

Guillaume Monneret, Muzhda Haem Rahimi, Anne-Claire Lukaszewicz, Fabienne Venet, Morgane Gossez

{"title":"Shadows and lights in sepsis immunotherapy.","authors":"Guillaume Monneret, Muzhda Haem Rahimi, Anne-Claire Lukaszewicz, Fabienne Venet, Morgane Gossez","doi":"10.1080/14656566.2024.2418987","DOIUrl":"10.1080/14656566.2024.2418987","url":null,"abstract":"Introduction: Sepsis remains a major global public health challenge. The host's response in sepsis involves both an exaggerated inflammatory reaction and immunosuppressive mechanisms. A better understanding of this response has shed light on the failure of anti-inflammatory therapies administered under the 'one size fits all' approach during the last decades.Areas covered: To date, patients' management has moved toward a comprehensive precision medicine approach that aims to personalize immunotherapy, whether anti-inflammatory or immunostimulatory. Large Prospective interventional randomized controlled trials validating this approach are about to start. A crucial prerequisite for these studies is to stratify patients based on biomarkers that will help defining the patients' immuno-inflammatory trajectory.Expert opinion: Some biomarkers are already available in routine clinical care, while improvements are anticipated through the standardized use of transcriptomics and other multi-omics technologies in this field. With these precautions in mind, it is reasonable to anticipate improvement in outcomes in sepsis.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2125-2133"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations. 银屑病的药物治疗：解决银屑病关节炎和皮肤表现问题。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-21 DOI: 10.1080/14656566.2024.2419563

Robin C Yi, Hannah Y Gantz, Shailey C Shah, Shannon K Moran, Yael E Klionsky, Steven R Feldman

{"title":"Pharmacotherapeutic management of psoriatic disease: addressing psoriatic arthritis and cutaneous manifestations.","authors":"Robin C Yi, Hannah Y Gantz, Shailey C Shah, Shannon K Moran, Yael E Klionsky, Steven R Feldman","doi":"10.1080/14656566.2024.2419563","DOIUrl":"10.1080/14656566.2024.2419563","url":null,"abstract":"Introduction: Psoriasis and psoriatic arthritis (PsA) are interrelated autoimmune conditions sharing similar genetic and immunological pathways. PsA often develops within 10 years of psoriasis onset, though it may precede cutaneous symptoms in some patients. Effective management of these conditions requires a multidisciplinary approach to address skin, bone, joint, and vascular manifestations.Areas covered: The review summarizes the current pharmacotherapies and to provide treatment guidelines for managing cutaneous psoriasis and PsA in psoriatic disease.Expert opinion: The management for mild psoriasis and mild PsA flare-ups can be addressed with topical treatments and with NSAIDs or intra-articular glucocorticoid injections. For more persistent or severe cases, systemic treatments with oral small molecules (Methotrexate, Apremilast, Janus kinase inhibitors) or with biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, CTLA-4 Ig) are effective in managing both psoriasis and PsA. With many treatment options, providers can tailor management, which considers patient disease severity, preference, comorbidities, and other factors. Early detection and a multidisciplinary management strategy can optimize patient quality of life and improve health outcomes.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2203-2212"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current and emerging opioids for the treatment of chronic cough: a mini review. 用于治疗慢性咳嗽的现有和新兴阿片类药物：微型综述。

IF 4.6 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-11-01 Epub Date: 2024-10-24 DOI: 10.1080/14656566.2024.2418983

Mengru Zhang, Alyn H Morice

{"title":"Current and emerging opioids for the treatment of chronic cough: a mini review.","authors":"Mengru Zhang, Alyn H Morice","doi":"10.1080/14656566.2024.2418983","DOIUrl":"10.1080/14656566.2024.2418983","url":null,"abstract":"Introduction: Chronic cough has increasingly been recognized as a distinct clinical entity that affects a significant portion of the global population. Despite advancements in understanding its pathophysiology, treatment options remain limited. Opioid analgesics have long been used for cough, and some have proven clear antitussive potential. However, these have yet to be approved by regulatory authorities for the treatment of chronic cough. Several novel synthetic opioid modulators that demonstrated antitussive effects in early-stage studies also failed to translate into clinical practice.Areas covered: This mini review aims to summarize the implications of opioid receptors in the development of cough medicines and highlight recent advances in opioid analgesics in cough trials. PUB MED/CINAHL/Web of Science/Scopus was searched (September 2024).Expert opinion: Our understanding of the precise sites of action and the involvement of peripheral opioid receptors in cough remains limited. Despite these gaps in knowledge, opioids remain a viable option for some patients until more novel effective treatments are available. Due to the frequent opioid side effects, new opioid derivatives with improved properties are needed. The development of tailored or biased delta-opioid receptor ligands and mixed agonists of opioid receptor-like 1/mu receptors may offer hope for new opioid-based drug discovery for chronic cough.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2167-2175"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria. 治疗阵发性夜间血红蛋白尿的色甘平。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-15 DOI: 10.1080/14656566.2024.2404110

Carlos M de Castro, Bhumika J Patel

{"title":"Iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.","authors":"Carlos M de Castro, Bhumika J Patel","doi":"10.1080/14656566.2024.2404110","DOIUrl":"https://doi.org/10.1080/14656566.2024.2404110","url":null,"abstract":"Introduction: Standard-of-care first-line treatments for paroxysmal nocturnal hemoglobinuria (PNH) include the anti-C5 therapies eculizumab and ravulizumab. However, persistent anemia, likely due to extravascular hemolysis, and reduced quality of life (QoL) due to frequent infusions remain concerns. Iptacopan is a first-in-class oral proximal complement inhibitor that targets factor B in the alternative pathway (upstream of C5), limiting intravascular and extravascular hemolysis.Areas covered: In patients previously treated with anti-C5 therapies or naive to complement inhibitors, iptacopan 200 mg twice daily resulted in clinically meaningful results in the pivotal phase 3 APPLY-PNH (NCT04558918) and APPOINT-PNH (NCT04820530) trials. Treatment with iptacopan was safe, and no treatment-related adverse events led to discontinuation.Expert opinion: APPLY-PNH and APPOINT-PNH reported clinically meaningful improvements in hemoglobin, bilirubin, and lactate dehydrogenase levels; transfusion avoidance; reticulocyte count; and fatigue. Iptacopan's safety profile was comparable to other complement inhibitors. Oral iptacopan therapy allows patients to avoid infusions, limit clinical visits, decrease medical costs, improve anemia that persists with other complement inhibitors, and improve QoL. Long-term follow-up will further assess infections, thrombosis, and breakthrough hemolysis. Before treatment, physicians need to discuss current therapeutic options with patients for shared decision-making. Guidelines are being created to assist healthcare professionals in this advancing field.","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"1-9"},"PeriodicalIF":2.5,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142461372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pediatric pharmacotherapy: a challenge with complex roots. 儿科药物治疗：根源复杂的挑战。

IF 2.5 3区医学

Expert Opinion on Pharmacotherapy Pub Date : 2024-10-13 DOI: 10.1080/14656566.2024.2415700

Klaus Rose

引用次数: 0